Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines

Experimental Hematology

Volumn 29, Issue 8, 2001, Pages 962-970

  Liu, Qun ^a   El Deiry, Wafik S ^b   Gazitt, Yair ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; ANNEXIN A5; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; GENES, BCL-2; GENES, P53; HLA-DR4 ANTIGEN; HLA-DR5 ANTIGEN; HUMANS; KINETICS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; MUTAGENESIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034899005     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(01)00677-4     Document Type: Article

References (55)

1. Effective treatment of multiple myeloma refractory to alkylating agents
2. High dose melphalan with autologous bone marrow transplantation for multiple myeloma
3. Combination chemotherapy vs melphalan and prednisone in the treatment of multiple myeloma; an overview of published trials
4. Alternating combination chemotherapy improves survival in multiple myeloma; A Southwest Oncology Group Study
5. Primary dexamethasone treatment for multiple myeloma
6. A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma
7. P53 in life and death
8. P53 function and dysfunction
9. The tumor suppressor gene and product
10. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo
11. Structure and function of P53 in normal cells and their aberration in cancer cells; Projection on the hematological cell lineages
12. Mutation of p53 gene in human myeloma cell lines
13. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy
14. Presence of p53 gene deletions in patients with MM predicts for short survival after conventional chemotherapy
15. Repression of IL-6 gene promoter by P53 and the retinoblastoma gene product
16. Modulation of IL-6 induced plasma protein secretion in hepatoma cells by p53 species
17. IL-6 in human multiple myeloma
18. Gene therapy for lung cancer; Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus mediated p53 gene transfer
19. In vivo molecular therapy with p53 Adenovirus for microscopic residual head and neck squamous carcinoma
20. Adenovirus mediated p53 gene therapy and paclitaxel have synergistic effect in models of human head and neck, ovarian, prostate and breast cancer
21. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
22. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
23. Adenovirus effectively targets cell lines derived from selected lymphocytic malignancies including anaplastic large cell lymphoma and Hodgkin's disease
24. Identification and characterization of a new member of the TNF family that induces apoptosis
25. Induction of apoptosis by apo-2 ligand, a new member of the tumor necrosis factor cytokine family
26. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB
27. Death receptors; Signaling and modulation
28. Intracellular regulation of Apo2L/TRAIL-induced apoptosis in human melanoma
29. An antagonistic decoy receptor and a death domain containing receptor for Apo2L/TRAIL
30. The antiapoptotic decoy receptor TRID/Apo2L/TRAIL-R3 is a p53 regulated DNA damage inducible gene that is overexpressed in primary tumors of the gastrointestinal tract
31. Control of Apo2L/TRAIL-induced apoptosis by a family of signaling and decoy receptors
32. Molecular determinants of response to Apo2L/TRAIL in killing of normal and cancer cells
33. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
34. Apo2/TRAIL dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
35. bcl-2 initiates a new category of oncogenes; Regulators of cell death
36. bcl-2 and programmed cell death
37. The bcl-2 protein family; Arbiters of cell survival
38. bcl-2 oncoprotein blocks chemotherapy induced apoptosis in human leukemia cell line
39. bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines; A study with inducible bcl-2 transfection constructs
40. The role of p53, bcl-2 and bax in dexamethasone induced apoptosis in myeloma cell lines
41. bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines
42. bcl-2 overexpression is associated with resistance to paclitaxel but not gemcitabine in multiple myeloma cell lines
43. bcl-2 overexpression is associated with resistance to dexamethasone but not melphalan in multiple myeloma cell lines
44. Apoptosis induced by Apo2L/TRAIL and TNF-α in human multiple myeloma cells is not blocked by bcl-2
45. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
46. + hematopoietic progenitor cells and normal lymphocytes
47. Safety and antitumor activity of recombinant soluble Apo2 ligand
48. Tumor necrosis factor-related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11
49. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
50. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor related apoptosis inducing ligand in vitro and in vivo
51. KILLER/DR5 is a DNA damage-inducible, p53 regulated death receptor gene
52. WAF-1 a potential mediator of p53 tumor suppression
53. Tumor necrosis factor related aoptosis inducing ligand retains its apoptoti-inducing capacity on bcl-2 or bclx/l overexpressing, chemotherapy-resistant cells
54. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis
55. Loss of Caspase 8 expression in highly malignant human neuroblastoma cells correlates with resistance to TRAIL-related apoptosis-inducing ligand-induced apoptosis